Cybin ( ($TSE:CYBN) ) has shared an announcement.
Cybin announced the launch of its first strategic partnership agreement with Segal Trials to support its multinational pivotal Phase 3 program for CYB003, designed to treat Major Depressive Disorder. This collaboration aims to enhance trial efficiency and performance, with the potential to expedite the approval process, while enrolling approximately 550 patients across more than 40 clinical sites in the U.S. and Europe.
More about Cybin
Cybin Inc. is a clinical-stage breakthrough neuropsychiatry platform company focused on revolutionizing mental healthcare through the development of innovative next-generation treatment options.
YTD Price Performance: -6.16%
Average Trading Volume: 351,440
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.37M
For an in-depth examination of CYBN stock, go to TipRanks’ Stock Analysis page.
